May 26, 2020 – Vancouver, BC – Geyser Brands Inc. (TSX-V: GYSR) (“Geyser Brands” or the “Company”) is pleased to announce the receipt of their Natural Product Number (NPN) from Health Canada for their hemp-based topical Eczema (Psoriasis) cream. Through the issuance of the NPN, products that carry an NPN have been assessed by Health Canada and found to be safe, effective and of high quality under their recommended conditions of use. The new product has proved to be very effective in the treatment of both Psoriasis & Eczema.
Geyser Brands' Solace subsidiary is authorized to market and sell their Eczema cream as a natural health product through the Apothecary Naturals and STōND Naturals line of products.
Solace will also be offering a version of this product through the brand Apothecary Labs in the regulated Cannabis market. Apothecary Labs will be using the same base product and adding CBD & THC.
According to a report Aug 2019 by Grand View Research, Inc., the global atopic dermatitis drugs market size is expected to reach USD 6.41 billion by 2022.
With distribution through traditional retailers and direct-to-consumer, products are expected to hit shelves in June, 2020. Regulated cannabis versions are expected to be available at government licensed dispensaries by August 2020.
The Solace subsidiary carries the Apothecary line of brands including:
• Apothecary Naturals: 100% all-natural, organic, hemp-based products for everything from skin care to pain relief.
"Receiving our NPN supports our vision to develop and build brands based on trust and credibility in an emerging but heavily regulated industry. Our continued focus on natural, healthy ingredients along with world-class formulations has been recognized with this NPN and we look forward to rolling these out in Canada as a first step in building a global presence", stated Geyser Brands Chairman, Brad Kersch.
ABOUT GEYSER BRANDS
Geyser Brands Inc. develops consumer product brands in the health and wellness sector that use hemp and CBD as a value-added ingredient. These involve next-generation formulas that focus on the mix of cannabinoids for specific conditions such as insomnia, anxiety and pain.
Proprietary delivery technologies include all natural nano-technology, slow-release mechanisms and non-molecule degrading baking processes. In anticipation of coming edibles legislation, and with its Health Canada approved Licensed Production Facility, Geyser Brands has 15,000 square feet in two GMP facilities in Vancouver, BC.
For more information, visit the company’s website at www.geyserbrands.com.
On Behalf of the Board of Directors
Director and CEO